The development, Implementation, and continued use of new vaccines depends on several factors.
Although disease burden seems like an obvious quantitative measure for setting priorities for new vaccine development and use, resources are not always allocated proportionately.
This Is particularly evident for diseases that are unique (or largely limited) to people In developing countries.
Public pressure based on perceptions of the risks associated with a disease or vaccine, the cost of new vaccines, and the ability to Incorporate them Into existing vaccination programmes also need to be considered in the decision to Introduce new vaccines.
Vaccine manufacturers play an Important part In development of new vaccines, and therefore, the issues that are important to them, namely, production, Intellectual property rights, and product liability, must be addressed.
By advocating rational decisions, supported by accurate Information, scientists and public-health professionals can have an important role In transforming the potential of new vaccines Into the reality of new vaccine-preventable diseases.
Mots-clés Pascal : Vaccination, Vaccin, Recherche scientifique, Développement, Nouveauté, Perception sociale, Opinion publique, Prévalence, Maladie, Aspect économique, Article synthèse, Politique sanitaire, Choix, Homme, Pays en développement, Prévention
Mots-clés Pascal anglais : Vaccination, Vaccine, Scientific research, Development, Novelty, Social perception, Public opinion, Prevalence, Disease, Economic aspect, Review, Health policy, Choice, Human, Developing countries, Prevention
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0005992
Code Inist : 002B30A03B. Création : 17/04/1998.